Precipio, Inc. (PRPO) can sell. Click on Rating Page for detail.
The price of Precipio, Inc. (PRPO) is 6.03 and it was updated on 2025-04-26 01:01:37.
Currently Precipio, Inc. (PRPO) is in undervalued.
News |
---|
![]() Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
|
![]() Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs
|
![]() Two Smaller Companies Worthy of Your "Attention"
|
![]() Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript
|
![]() Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
|
StockPrice Release |
---|
![]() Precipio signs another hemescreen™ customer
|
![]() Precipio terminates its equity line
|
News |
---|
Precipio Announces Employee Stock Option Plan Repricing
|
Zacks Initiates Coverage of Precipio With Outperform Recommendation
|
Precipio, Inc. (PRPO) Q2 2024 Earnings Call Transcript
|
Precipio Announces Q2-2024 Shareholder Update Call
|
Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
|
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
|
Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
|
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
|
Precipio Secures a short-term $500K Credit Facility
|
Precipio Announces Year end 2023 Shareholder Update Call
|
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
|
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
|
Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
|
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
|
Precipio Announces Christina Valauri joins the Board of Directors
|
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
|
Precipio, Inc. (PRPO) Q3 2023 Earnings Call Transcript
|
Precipio Announces Q3-2023 Shareholder Update Call
|
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
|
Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
|
Precipio Continues to Sign New HemeScreen™ Customers
|
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
|
Precipio Takes Final Step Towards Regaining Nasdaq Compliance
|
Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
|
Precipio, Inc. (PRPO) Q2 2023 Earnings Call Transcript
|
Precipio Announces Q2-2023 Shareholder Update Call
|
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
|
Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
|
Precipio, Inc. (PRPO) Q1 2023 Earnings Call Transcript
|
Precipio, Inc. (PRPO) Q4 2022 Earnings Call Transcript
|
Precipio, Inc. (PRPO) Q3 2022 Earnings Call Transcript
|
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2022 Results - Earnings Call Transcript
|
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
|
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q4 2021 Results - Earnings Call Transcript
|
Best Penny Stocks to Buy Today? 3 For Your Watchlist Right Now
|
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q3 2021 Results - Earnings Call Transcript
|
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2021 Results - Earnings Call Transcript
|
American Oncology Network Partners with Precipio to Bring HemeScreen® into AON's Laboratory
|
Precipio Reschedules Q2-2021 Shareholder Update Call
|
Precipio Announces Q2-2021 and year-end Shareholder Update Call
|
Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M
|
5 Top Penny Stocks Insiders Decided To Buy In June 2021
|
Precipio Terminates its Equity Line
|
Can Penny Stocks Make You Rich? Check These 4 Small-Caps Out
|
Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool
|
This is Why Shareholders Are Fired Up About Precipio Stock
|
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q1 2021 Results - Earnings Call Transcript
|
Reddit Penny Stocks To Buy Now? 3 To Watch After Crypto Crash
|
A Widely Available Covid-19 Test Enhances Precipio's Value
|
Which Penny Stocks Are The Most Resilient During a Bear Market?
|
3 Reddit Penny Stocks to Watch That You May Have Missed Last Week
|
Precipio Announces Q1-2021 and year-end Shareholder Update Call
|
4 Biotech Penny Stocks That You Need to Know About
|
PRPO Stock: Over 35% Increase Intraday Explanation
|
Market Update: The 10 Most Volatile Stocks Today
|
Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time
|
7 Reddit Penny Stocks With Interesting Plans
|
5 Reddit Penny Stocks Seeing the Most Chatter Thursday
|
Top Penny Stocks For Your Thursday Morning Watchlist
|
Precipio extends 2-day gain to 404% following launch of the company's COVID-19 test on Amazon
|
5 Reddit Penny Stocks Seeing the Most Chatter Tuesday
|
4 Hot Penny Stocks To Watch In May 2021
|
PRPO Stock: From $4.95 To $6.97 (37.17% Increase) After Hours Explanation
|
Precipio Surges 140%, Breaks Out Of A Falling Wedge Pattern
|
PRPO Stock: 12 Things to Know about the Precipio Rapid COVID-19 Antibody Test Launch on Amazon
|
PPRO Stock: From $1.82 To $2.50 Intraday Explanation
|
Precipio Launches its Rapid COVID-19 Antibody test on Amazon Platform
|
Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio's HemeScreen POL Offering by Q4-2021
|
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q4 2020 Results - Earnings Call Transcript
|
PRPO Increased Over 5% Pre-Market: Why It Happened
|
Precipio Announces Q4-2020 and year-end Shareholder Update Call
|
Mr. Ron Andrews joins Precipio's Board of Directors
|
Mr. Richard Sandberg is appointed Chairman of Precipio's Board of Directors
|
Precipio Launches COVID-19 Antibody Testing at Point-of-Care
|
Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
|
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
|
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q3 2020 Results - Earnings Call Transcript
|
Precipio Announces Q3-2020 Shareholder Update Call
|